Biguanides have been more extensively studied and a randomized placebo-controlled crossover study with metformin in non-diabetes patients with MCI due to AD, revealed no significant changes in CSF levels of Aβ42, Total tau, or phospho-tau after 8 weeks of treatment, although these results were based on pilot data [305]. The gene discussed is MAPT; the disease is Alzheimer disease.